Clinical trials: Hyperalimentation and Obesity

Prader-Willi Syndrome

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

• Withdrawn
• Age: 13 to 65 years
• Phase 2

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.

Trial name

PWS (NCT05198362)

Testing

Tesomet

Where

United States

Sponsor

Saniona